NCT05980884

Using Gut Microbial Gbu Gene Testing to Estimate Host TMAO Production Capacity

Evaluation of Microbial-derived TMAO Production From Carnitine Intake by Testing Fecal Gbu Gene

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 230 (estimated)
• Sponsor: National Taiwan University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The risk of cardiovascular diseases from red meat consumption varies among individuals due to variations in gut microbiota. L-carnitine in red meat can be converted to TMAO in the body by certain bacteria. Not everyone experiences a significant increase in TMAO levels after consuming carnitine. Gut microbiota differences are observed between high and low TMAO producers. The presence of the gbu gene in gut microbiota is linked to TMAO production. This clinical research aims to determine if the gbu gene can predict TMAO levels after dietary carnitine intake.

Detailed description

The risk of developing cardiovascular diseases due to the consumption of red meat varies among individuals, and this may be attributed to differences in the composition and function of gut microbiota. Studies have found that red meat, rich in L-carnitine, may be metabolized by certain anaerobic bacteria in the intestines to produce trimethylamine N-oxide (TMAO) in the human body. Previous research utilizing the oral carnitine challenge test (OCCT) revealed that not everyone experiences a significant increase in blood TMAO levels after consuming carnitine. Moreover, individuals with high TMAO production and low TMAO production showed distinct differences in their gut microbiota. Furthermore, we have discovered a significant correlation between the abundance of the gbu gene in gut microbiota and the production of TMAO in response to dietary carnitine intake. Therefore, through the design of clinical research, we aim to investigate and assess whether the abundance of the gbu gene in gut microbiota can predict the levels of TMAO produced in the human body under dietary carnitine intake.

Conditions

• Gut Dysbiosis for TMAO Production From L-carnitine Consumption

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	L-carnitine	Participants are required to take a capsule containing 500mg L-carnitine/day continuous for 7-10 days.

Timeline

• Start date: 2023-07-24
• Primary completion: 2026-04-25
• Completion: 2026-07-30
• First posted: 2023-08-08
• Last updated: 2026-01-12

Locations

1 site across 1 country: Taiwan